Chapter 2 - University of British Columbia

51. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A,
You MJ, Aguirre AJ et al: High-resolution genomic profiles of human lung cancer.
Proc Natl Acad Sci U S A 2005, 102(27):9625-9630.
52. Lockwood WW, Chari R, Coe BP, Girard L, Macaulay C, Lam S, Gazdar AF, Minna JD,
Lam WL: DNA amplification is a ubiquitous mechanism of oncogene activation in
lung and other cancers. Oncogene 2008, 27(33):4615-4624.
53. Cavenee WK: Loss of heterozygosity in stages of malignancy. Clin Chem 1989,
35(7 Suppl):B48-52.
54. Bepler G, Garcia-Blanco MA: Three tumor-suppressor regions on chromosome 11p
identified by high-resolution deletion mapping in human non-small-cell lung
cancer. Proc Natl Acad Sci U S A 1994, 91(12):5513-5517.
55. Fong KM, Zimmerman PV, Smith PJ: Microsatellite instability and other molecular
abnormalities in non-small cell lung cancer. Cancer Res 1995, 55(1):28-30.
56. Merlo A, Gabrielson E, Askin F, Sidransky D: Frequent loss of chromosome 9 in
human primary non-small cell lung cancer. Cancer Res 1994, 54(3):640-642.
57. Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB, Sidransky D: Homozygous
deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in
primary human small cell lung cancer. Cancer Res 1994, 54(9):2322-2326.
58. Sundaresan V, Heppell-Parton A, Coleman N, Miozzo M, Sozzi G, Ball R, Cary N,
Hasleton P, Fowler W, Rabbitts P: Somatic genetic changes in lung cancer and
precancerous lesions. Ann Oncol 1995, 6 Suppl 1:27-31; discussion 31-22.
59. Huang J, Wei W, Chen J, Zhang J, Liu G, Di X, Mei R, Ishikawa S, Aburatani H, Jones
KW et al: CARAT: a novel method for allelic detection of DNA copy number
changes using high density oligonucleotide arrays. BMC Bioinformatics 2006, 7:83.
60. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A,
Kurokawa M, Chiba S, Gilliland DG et al: Highly sensitive method for genomewide
detection of allelic composition in nonpaired, primary tumor specimens by use of
affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum
Genet 2007, 81(1):114-126.
61. LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, Harrington D, Sellers WR,
Meyerson M: Allele-specific amplification in cancer revealed by SNP array
analysis. PLoS Comput Biol 2005, 1(6):e65.
62. Li C, Beroukhim R, Weir BA, Winckler W, Garraway LA, Sellers WR, Meyerson M: Major
copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics
2008, 9:204.
63. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C: dChipSNP: significance
curve and clustering of SNP-array-based loss-of-heterozygosity data.
Bioinformatics 2004, 20(8):1233-1240.
64. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C,
Greulich H, Muzny DM, Morgan MB et al: Somatic mutations affect key pathways in
lung adenocarcinoma. Nature 2008, 455(7216):1069-1075.
65. Suda K, Tomizawa K, Mitsudomi T: Biological and clinical significance of KRAS
mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
Cancer Metastasis Rev 2010.
66. Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature
2007, 447(7143):433-440.
67. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M: Reduced genomic 5-methylcytosine
content in human colonic neoplasia. Cancer Res 1988, 48(5):1159-1161.
68. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer 2004,
4(2):143-153.
69. Lo PK, Sukumar S: Epigenomics and breast cancer. Pharmacogenomics 2008,
9(12):1879-1902.
70. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs
R D 2003, 4(3):179-184.
21